生物标誌物交易：合约价值与趋势（2019-2025）

本报告对全球生物标誌物市场的策略交易（包括许可、收购和合作）进行了分析。

它重点关注 2019 年至 2025 年期间执行的交易，对交易活动进行回顾性评估，以确定生物标誌物领域的新兴趋势、投资行动和策略重点。

调查范围

这份名为《生物标记交易：交易价值与趋势（2019-2025）》的报告全面分析了全球生物标记产业的策略交易，包括授权、收购和合作。报告重点关注2019年至2025年期间达成的交易，并对交易活动进行回顾性评估，以识别生物标记领域的新兴趋势、投资行动和策略重点。

为了识别生物标记产业的新兴趋势、投资行为和策略重点，本报告重点关注2019年至2025年期间达成的交易，反映交易条款、交易价值和交易结构等方面的实际情况。报告透过实际案例，对交易条款进行了深入分析，包括预付款、里程碑式薪酬、特许权使用费安排和终止条款。

除了交易分析之外，该报告还深入回顾了影响生物标记开发和商业化市场的市场动态，强调了市场驱动因素、限制因素、机会和挑战，以及该领域的新兴技术。

总体而言，本报告为寻求了解生物标记伙伴关係现状的潜在交易商提供了宝贵的资源。它提供了企业如何合作研究、开发和商业化生物标记技术的可行见解，帮助他们在这个快速发展的领域中做出明智的决策。

报告内容

• 生物标誌物产业现状概述、近期的授权协议、市场合作和收购
• 本报告涵盖影响生物标记市场发展的关键公司、趋势、障碍和其他资讯。
• 回顾市场中的交易条款，重点关注关键交易趋势、涉及的公司，并进一步分析潜在的许可、合作和收购机会
• 为潜在交易商提供有关生物标誌物技术和产品研发和商业化合作的重要讯息
• 有关生物标誌物行业许可、收购和合作交易的关键要素的信息
• 三角测量方法调查方法和重要细节，例如专利研究和分析、临床试验研究和分析
• 不同类型的生物标誌物交易、里程碑付款的详细资讯及其在各种交易中的价值
• 生物标誌物专利格局分析
• 主要企业，包括赛默飞世尔科技公司 (Thermo Fisher Scientific Inc.)、F. Hoffmann-La Roche Ltd.、Illumina Inc.、Bio-Rad Laboratories Inc. 和安捷伦科技公司 (Agilent Technologies Inc.)。

目录

第一章执行摘要

第二章 市场概况

• 概述
• 生物标记分类
• 生物标誌范例

第三章 市场动态

• 概述
• 市场驱动因素
• 疾病发病率上升
• 体学和成像技术的进展
• 市场限制
• 开发成本
• 对技术纯熟劳工的需求
• 市场机会
• 新兴市场
• 个人化医疗
• 市场挑战
• 技术挑战
• 监管和检验的复杂性

第四章 新兴科技与发展

• 概述
• 关键要点
• 新兴技术
• 基因组学
• 蛋白质体学
• 代谢体学
• 影像学
• 生物资讯学

第五章 收购、合作及授权协议

• 生物标记市场许可协议（2019-2025）
• 许可协议的定义和一般结构
• 估值和结算结构
• 生物标记市场许可协议分析（2019-2025）
• 生物标誌物市场收购（2019-2025）
• 收购的定义和一般结构
• 生物标记市场收购分析（2019-2025）
• 生物标记市场伙伴关係/合作（2019-2025）
• 合作的定义和整体结构
• 生物标记市场伙伴关係/协作分析（2019-2025）
• 生物标誌物市场交易的进一步分析
• 许可协议结构分析（2019-2025）
• 生物标誌物产业收购结构（2019-2025）
• 生物标记市场的合作伙伴结构（2019-2025）

第六章：生物标记专利格局

• 专利态势亮点
• 专利审查

第七章 附录

• 调查方法
• 资讯来源
• 简称
• 公司简介
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BAYER AG
• BD
• BIOFOURMIS
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• BRUKER
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• ILLUMINA INC.
• MERCK KGAA
• QIAGEN
• REVVITY
• THERMO FISHER SCIENTIFIC INC.

This report provides an analysis of strategic transactions encompassing licensing, acquisitions and collaborations in the global biomarker market. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.

Report Scope

This report, Biomarker Deals: Terms, Value and Trends 2019-2025, offers a comprehensive analysis of strategic transactions, encompassing licensing, acquisitions and collaborations, in the global biomarkers industry. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.

The chosen time frame reflects the factual nature of deal terms, values and structures, which cannot be accurately forecast. The report provides insights into terms of contracts, such as up-front payments, milestone-based compensation, royalty arrangements and termination clauses, supported by real-world case examples.

In addition to transaction analysis, the report provides an in-depth review of market dynamics, highlighting the drivers, restraints, opportunities and challenges influencing the market for biomarker development and commercialization. It also covers emerging technologies in the sector.

Overall, this report serves as a resource for prospective dealmakers seeking to understand the current state of biomarker partnerships. It offers actionable insights into how companies are structuring collaborations for the R&D and commercialization of biomarker technologies, supporting informed decision-making in this rapidly evolving field.

Report Includes

• An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including a comprehensive analysis of deal structures and their potential values
• Coverage of significant companies in this study, trends and obstacles and other information affecting the development of the biomarker market
• Review of business terms and conditions of deals in the market, with focus on major trends in deal-making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
• Information essential to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
• Information about the main elements in licensing, acquisitions and partnership deals in the biomarker industry
• Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis, et al.
• Details on various types of biomarkers deals and milestone payments and their value in different deals
• Analysis of the patent landscape featuring biomarkers
• Profiles of the leading companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Classification of Biomarkers
• Examples of Biomarkers

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Rising Incidence of Diseases
• Advances in Omics and Imaging Technologies
• Market Restraints
• Development Costs
• Need for Skilled Labor
• Market Opportunities
• Emerging Markets
• Personalized Medicine
• Market Challenges
• Technical Challenges
• Regulatory and Validation Complexity

Chapter 4 Emerging Technologies and Developments

• Overview
• Key Takeaways
• Emerging Technologies
• Genomics
• Proteomics
• Metabolomics
• Imaging
• Bioinformatics

Chapter 5 Acquisitions, Collaborations, and Licensing Deals

• Licensing Deals in the Biomarker Market, 2019 to 2025
• Definition and General Structure of Licensing Deals
• Valuation and Payment Structure
• Analysis of Licensing Deals in the Biomarker Market, 2019 to 2025
• Acquisitions in the Biomarker Market, 2019 to 2025
• Definition and General Structure of Acquisitions
• Analysis of Acquisitions in the Biomarker Market, 2019 to 2025
• Partnerships/Collaborations in Biomarker Market, 2019 to 2025
• Definition and General Structure of Collaborations
• Analysis of Partnerships/Collaborations in the Biomarkers Market, 2019 to 2025
• Further Analysis of Deals in the Biomarker Market
• Analysis of Structure of Licensing Deals, 2019 to 2025
• Structure of Acquisitions in the Biomarker Industry, 2019 to 2025
• Structure of Collaborations in the Biomarker Market, 2019 to 2025

Chapter 6 Biomarker Patent Landscape

• Patent Landscape Takeaways
• Patent Review

Chapter 7 Appendix

• Methodology
• Information Sources
• Abbreviations
• Company Profiles
• ABBOTT
• AGILENT TECHNOLOGIES INC.
• BAYER AG
• BD
• BIOFOURMIS
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• BRUKER
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• ILLUMINA INC.
• MERCK KGAA
• QIAGEN
• REVVITY
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table : Biomarker Licensing Deals, Acquisitions and Partnerships, by Type, 2021-2025
• Table 1 : Categories of Biomarkers
• Table 2 : Examples of Biomarkers
• Table 3 : Forms of Payment in Licensing Deals
• Table 4 : Number of Biomarker Licensing Deals in Biotech Sectors, 2019-2025
• Table 5 : Biomarker Licensing Deals, 2019-2025
• Table 6 : Number of Biomarker Licensing Deals in Pathological Sectors, 2019-2025
• Table 7 : Goals of Biomarker Licensing Deals, 2019-2025
• Table 8 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
• Table 9 : Number of Biomarker Acquisitions in Biotech Sectors, 2019-2025
• Table 10 : Biomarker Acquisitions, 2019-2025
• Table 11 : Number of Biomarker Acquisitions in Different Pathological Sectors, 2019-2025
• Table 12 : Goals of Biomarker Acquisitions, 2019-2025
• Table 13 : Number of Biomarker Collaborations in Biotech Sectors, 2019-2025
• Table 14 : Partnerships/Collaborations in the Biomarker Market, 2019-2025
• Table 15 : Number of Biomarker Collaborations in Pathological Sectors, 2019-2025
• Table 16 : Goals of Biomarker Collaborations, 2019-2025
• Table 17 : Up-Front Payments in Licensing Deals in the Biomarker Market, 2019-2025
• Table 18 : Milestone and Royalty Payments in Licensing Deals, 2019-2025
• Table 19 : Termination Conditions in Licensing Deals, 2019-2024
• Table 20 : Value of Biomarker Licensing Deals Worldwide, 2021-2025
• Table 21 : Acquisitions in the Biomarker Industry, 2020-2024
• Table 22 : Global Value of Biomarker Acquisitions, 2021-2025
• Table 23 : Up-Front Payments and Total Value in Collaboration Deals, 2019-2025
• Table 24 : Percentage of Up-Front Payments from Total Value in Collaborations, 2019-2025
• Table 25 : Milestones and Royalty Payments in Collaborations in the Biomarker Market, 2019-2025
• Table 26 : Number of Patents and Patent Applications Filed for Biomarkers, by Year, 2019-2024
• Table 27 : Patents and Patent Applications Filed for Biomarkers, 2019-2024
• Table 28 : Number of Patents and Patent Applications for Biomarkers, by Company, 2019-2024
• Table 29 : Information Sources for this Report
• Table 30 : Abbreviations Used in this Report
• Table 31 : Abbott: Company Snapshot
• Table 32 : Abbott: Financial Performance, FY 2023 and 2024
• Table 33 : Abbott: Product Portfolio
• Table 34 : Abbott: News/Key Developments, 2023 and 2024
• Table 35 : Agilent Technologies Inc.: Company Snapshot
• Table 36 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
• Table 37 : Agilent Technologies Inc.: Product Portfolio
• Table 38 : Agilent Technologies Inc.: News/Key Developments, 2023 and 2024
• Table 39 : Bayer AG: Company Snapshot
• Table 40 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 41 : Bayer AG: Product Portfolio
• Table 42 : Bayer AG: News/Key Developments, 2024
• Table 43 : BD: Company Snapshot
• Table 44 : BD: Financial Performance, FY 2023 and 2024
• Table 45 : BD: Product Portfolio
• Table 46 : BD: News/Key Developments, 2024
• Table 47 : Biofourmis: Company Snapshot
• Table 48 : Biofourmis: Product Portfolio
• Table 49 : Biofourmis: News/Key Developments, 2020 and 2024
• Table 50 : bioMerieux: Company Snapshot
• Table 51 : bioMerieux: Financial Performance, FY 2023 and 2024
• Table 52 : bioMerieux: Product Portfolio
• Table 53 : bioMerieux: News/Key Developments, 2024
• Table 54 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 55 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
• Table 56 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 57 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024
• Table 58 : Bruker: Company Snapshot
• Table 59 : Bruker: Financial Performance, FY 2023 and 2024
• Table 60 : Bruker: Product Portfolio
• Table 61 : Bruker: News/Key Developments, 2023
• Table 62 : Danaher Corp.: Company Snapshot
• Table 63 : Danaher Corp.: Financial Performance, FY 2023 and 2024
• Table 64 : Danaher Corp.: Product Portfolio
• Table 65 : Danaher Corp.: News/Key Developments, 2022-2024
• Table 66 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 67 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 68 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 69 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
• Table 70 : Illumina Inc.: Company Snapshot
• Table 71 : Illumina Inc.: Financial Performance, FY 2023 and 2024
• Table 72 : Illumina Inc.: Product Portfolio
• Table 73 : Illumina Inc.: News/Key Developments, 2024
• Table 74 : Merck KGaA: Company Snapshot
• Table 75 : Merck KGaA: Financial Performance, FY 2023 and 2024
• Table 76 : Merck KGaA: Product Portfolio
• Table 77 : Merck KGaA: News/Key Developments, 2024
• Table 78 : Qiagen: Company Snapshot
• Table 79 : Qiagen: Financial Performance, FY 2023 and 2024
• Table 80 : Qiagen: Product Portfolio
• Table 81 : Qiagen: News/Key Developments, 2023 and 2024
• Table 82 : Revvity: Company Snapshot
• Table 83 : Revvity: Financial Performance, FY 2023 and 2024
• Table 84 : Revvity: Product Portfolio
• Table 85 : Revvity: News/Key Developments, 2022 and 2023
• Table 86 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 87 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 88 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 89 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024

List of Figures

• Figure 1 : Market Dynamics Snapshot
• Figure 2 : Share of Biomarker Licensing Deals, by Therapeutic Area, 2019-2025
• Figure 3 : Share of Biomarker Licensing Deals, by Goal, 2019-2025
• Figure 4 : Share of Licensing Deals Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
• Figure 5 : Share of Biomarker Acquisitions in Pathological Sectors, 2019-2025
• Figure 6 : Share of Biomarker Acquisitions, by Goal, 2019-2025
• Figure 7 : Share of Biomarker Collaborations in Biotech Sectors, by Year, 2019-2025
• Figure 8 : Share of Biomarker Collaborations in Pathological Sectors, 2019-2025
• Figure 9 : Share of Biomarker Collaborations, by Goal, 2019-2025
• Figure 10 : Share of Collaborations Between Companies and Academic Institutions vs. Between Two Companies, 2019-2025
• Figure 11 : Abbott: Revenue Share, by Business Unit, FY 2024
• Figure 12 : Abbott: Revenue Share, by Country/Region, FY 2024
• Figure 13 : Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 14 : Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 15 : Bayer AG: Revenue Share, by Business Unit, FY 2024
• Figure 16 : Bayer AG: Revenue Share, by Country/Region, FY 2024
• Figure 17 : BD: Revenue Share, by Business Unit, FY 2024
• Figure 18 : BD: Revenue Share, by Country/Region, FY 2024
• Figure 19 : bioMerieux: Revenue Share, by Business Unit, FY 2024
• Figure 20 : bioMerieux: Revenue Share, by Country/Region, FY 2024
• Figure 21 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 22 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 23 : Bruker: Revenue Share, by Business Unit, FY 2024
• Figure 24 : Bruker: Revenue Share, by Business Unit, FY 2024
• Figure 25 : Danaher Corp.: Revenue Share, by Business Unit, FY 2024
• Figure 26 : Danaher Corp.: Revenue Share, by Country/Region, FY 2024
• Figure 27 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 28 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 29 : Illumina Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 30 : Illumina Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 31 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
• Figure 32 : Merck KGaA: Revenue Share, by Country/Region, FY 2024
• Figure 33 : Qiagen: Revenue Share, by Business Unit, FY 2024
• Figure 34 : Qiagen: Revenue Share, by Country/Region, FY 2024
• Figure 35 : Revvity: Revenue Share, by Business Unit, FY 2024
• Figure 36 : Revvity: Revenue Share, by Country/Region, FY 2024
• Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
• Figure 38 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024